---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-234890"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2026-05-21T21:16:19+00:00"
generated_at: "2026-05-21T21:22:45.529552+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Whitehawk Therapeutics expands ADC pipeline with option for CPT113 in up to five new programs

## Summary
- Option agreement with Hangzhou DAC provides access to CPT113 for up to five internally developed ADC programs, including dual-payload variations.
- DXC006 data from Hangzhou DAC accepted for oral presentation at ASCO; J&J disclosed an ADC using CPT113 at AACR.
- PTK7-directed HWK-007 completed first dose cohort at 2 mg/kg, enrolling second cohort at 4 mg/kg; MUC16-directed HWK-016 enrolling first cohort at 2.5 mg/kg.
- Phase 1 dose-escalation data for HWK-007 and HWK-016 expected in first half of 2027; IND for HWK-206 anticipated mid-2026.
- Whitehawk retains global rights and full program control for new ADCs; anticipates IND submissions for multiple programs over next 12-24 months.

## SEC filing metadata
- accession: 0001193125-26-234890
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2026-05-21T21:16:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312526234890/0001193125-26-234890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312526234890/d32951d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-234890
- JSON: https://secwatch.observer/filing/0001193125-26-234890.json
- Plain text: https://secwatch.observer/filing/0001193125-26-234890.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.